Shares of Puma Biotechnology Inc. (NYSE:PBYI) rose 20.3 percent Friday on word that the company has submitted an FDA new drug application (NDA) for its lead candidate, neratinib, along with updated data showing that the drug's absolute invasive disease-free survival (DFS) benefit remained steady over time during a phase III study including the company's initial intent-to-treat (ITT) population, women with early stage HER2-positive breast cancer previously treated with Herceptin (trastuzumab, Roche AG).